title: Cellular localization and functional characterization of the equilibrative nucleoside transporters of antitumor nucleosides.
abstract: Nucleoside transporters play an important role in the disposition of nucleosides and their analogs. To elucidate the relationship between chemosensitivity to antitumor nucleosides and the functional expression of equilibrative nucleoside transporters (ENT), we established stable cell lines of human fibrosarcoma HT-1080 and gastric carcinoma TMK-1 that constitutively overexpressed green fluorescent protein-tagged hENT1, hENT2, hENT3 and hENT4. Both hENT1 and hENT2 were predictably localized to the plasma membrane, whereas hENT3 and hENT4 were localized to the intracellular organelles. The chemosensitivity of TMK-1 cells expressing hENT1 and hENT2 to cytarabine and 1-(3-C-ethynyl-beta-D-ribopentofuranosyl) cytosine increased markedly in comparison to that of mock cells. However, no remarkable changes in sensitivity to antitumor nucleosides were observed in cell lines that expressed both hENT3 and hENT4. These data suggest that hENT3 and hENT4, which are mainly located in the intracellular organelles, are not prominent nucleoside transporters like hENT1 and hENT2, which are responsible for antitumor nucleoside uptake.
authors: Department of Experimental Therapeutics, Cancer Research Institute, Kanazawa University, Kanazawa 920-0934, Japan. yendo@kenroku.kanazawa-u.ac.jp
authors: Yoshio
authors: Y
authors: Endo
authors: Tohru
authors: T
authors: Obata
authors: Daigo
authors: D
authors: Murata
authors: Mariho
authors: M
authors: Ito
authors: Kazuki
authors: K
authors: Sakamoto
authors: Masakazu
authors: M
authors: Fukushima
authors: Yasundo
authors: Y
authors: Yamasaki
authors: Yuji
authors: Y
authors: Yamada
authors: Nagato
authors: N
authors: Natsume
authors: Takuma
authors: T
authors: Sasaki
mesh_terms: D000964:Antimetabolites, Antineoplastic / Q000494:pharmacology*; D001692:Biological Transport; D002462:Cell Membrane / Q000378:metabolism*; D049109:Cell Proliferation / Q000187:drug effects*; D003561:Cytarabine / Q000494:pharmacology*; D003562:Cytidine / Q000031:analogs & derivatives* / Q000494:pharmacology; D033705:Equilibrative Nucleoside Transport Proteins / Q000235:genetics / Q000378:metabolism; D033721:Equilibrative Nucleoside Transporter 1 / Q000235:genetics / Q000378:metabolism; D033722:Equilibrative-Nucleoside Transporter 2 / Q000235:genetics / Q000378:metabolism; D005354:Fibrosarcoma / Q000188:drug therapy / Q000378:metabolism; D049452:Green Fluorescent Proteins / Q000378:metabolism; D006801:Humans; D033703:Nucleoside Transport Proteins / Q000235:genetics / Q000378:metabolism*; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D013274:Stomach Neoplasms / Q000188:drug therapy / Q000378:metabolism; D014407:Tumor Cells, Cultured / Q000187:drug effects
chemical_list: C103084:1-(3-C-ethynylribopentofuranosyl)cytosine; D000964:Antimetabolites, Antineoplastic; D033705:Equilibrative Nucleoside Transport Proteins; D033721:Equilibrative Nucleoside Transporter 1; D033722:Equilibrative-Nucleoside Transporter 2; D033703:Nucleoside Transport Proteins; D012333:RNA, Messenger; C438649:SLC29A1 protein, human; C438654:SLC29A2 protein, human; C501424:SLC29A3 protein, human; C495988:SLC29A4 protein, human; C485184:enhanced green fluorescent protein; D003561:Cytarabine; D049452:Green Fluorescent Proteins; D003562:Cytidine
references: J Med Chem. 1996 Dec 6;39(25):5005-11
references: 8960561
references: Semin Oncol. 1995 Aug;22(4 Suppl 11):3-10
references: 7481842
references: Mol Med Today. 1999 May;5(5):216-24
references: 10322314
references: Cancer Sci. 2004 Sep;95(9):753-7
references: 15471562
references: Gan. 1984 Aug;75(8):690-8
references: 6489676
references: J Biol Chem. 2004 Nov 26;279(48):50042-9
references: 15448143
references: Jpn J Cancer Res. 2001 Jul;92(7):793-8
references: 11473731
references: Nucleic Acids Symp Ser. 1997;(37):137-8
references: 9586037
references: Cancer Lett. 1997 Jun 24;116(2):225-31
references: 9215867
references: Pharm Biotechnol. 1999;12:313-52
references: 10742981
references: Cancer Res. 1984 Nov;44(11):5029-37
references: 6091869
references: Drug Metab Dispos. 2004 Oct;32(10):1178-82
references: 15280220
references: Pflugers Arch. 2004 Feb;447(5):735-43
references: 12838422
references: Biochim Biophys Acta. 1996 Oct 29;1286(3):153-81
references: 8982282
references: Jpn J Cancer Res. 2001 Mar;92(3):343-51
references: 11267946
references: J Med Chem. 1991 Sep;34(9):2917-9
references: 1895307
references: Cancer Lett. 1998 Jan 16;123(1):53-61
references: 9461018
references: Leuk Res. 2002 Jul;26(7):621-9
references: 12008078
references: Cancer Res. 1989 Jun 1;49(11):3015-9
references: 2720661
references: Nucleosides Nucleotides Nucleic Acids. 2001 Apr-Jul;20(4-7):609-19
references: 11563078
references: Cancer Res. 1992 May 1;52(9):2389-93
references: 1568208
references: J Biol Chem. 2002 Oct 4;277(40):37711-7
references: 12097333
references: Eur J Pharmacol. 2003 Oct 31;479(1-3):269-81
references: 14612157
references: Circ Res. 2006 Sep 1;99(5):510-9
references: 16873718
references: Virus Res. 2005 Feb;107(2):151-64
references: 15649561
references: J Biol Chem. 2005 Apr 22;280(16):15880-7
references: 15701636
references: Int J Mol Med. 2001 Sep;8(3):273-8
references: 11494055
references: Mol Membr Biol. 2001 Jan-Mar;18(1):53-63
references: 11396612
references: Cancer Lett. 1992 May 30;64(1):67-74
references: 1596880
references: Nucleosides Nucleotides. 1999 Apr-May;18(4-5):811-4
references: 10432683
references: Curr Drug Targets. 2003 May;4(4):305-13
references: 12699351
references: Pflugers Arch. 2004 Feb;447(5):728-34
references: 12856181
references: Cancer Res. 1987 Feb 15;47(4):936-42
references: 3802100
references: Curr Drug Metab. 2004 Feb;5(1):63-84
references: 14965251